Login to Your Account

Santaris Gets $700M From GSK In Antiviral LNA-Based Drug Pact

By Cormac Sheridan

Wednesday, December 26, 2007
Christmas has come early this year for Santaris Pharma A/S. Just one day after closing a new financing round of €20.4 million (US$29.4 million), the Copenhagen, Denmark-based company unveiled a broadly based drug discovery and development alliance with GlaxoSmithKline plc that could be worth more than $700 million in up-front, milestone and equity payments. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription